Biotech Stocks Surge to Record Highs on 'Explosive' Results

On Tuesday, shares of biotech companies Roivant and Pharvaris soared to all-time highs following outstanding results for treatments targeting lung and swelling disorders. The stocks of Roivant and Pharvaris rallied sharply after achieving results described as "explosive" and a "bull case scenario." The news propelled Roivant and Pharvaris into record-high territory, drawing investor attention and leading to significant increases in both companies' market capitalizations.